European Leukemia Trial Registry
Trial: JNJ-56022473AML2002

More Details
Title Phase II Studie zu Decitabine allein oder mit JNJ-56022473 (Anti CD123) bei AML-Patienten, für die keine intensive Chemotherapie möglich ist
Scientific Title A Randomized Phase 2 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
Short Title JNJ-56022473AML2002
Trialgroup NN
Type of Trial multicentric, randomized, prospective, open-label, double-group
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 65 years
Status Active
Start of Recruitment 01.04.2016
Leader Brandts, Prof. Dr. med., Christian
Shortprotocol Shortprotocol
created 11.04.2016 Zenawit Krüger
changed 13.04.2016 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org